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Health Technology Assessment in Poland) for orphan oncology drugs are based.
The role of AHTAPol is to prepare for the Minister of Health recommendations on
financing all medical technologies from public funds. Orphan oncology drugs un-
dergo pharmacoeconomic evaluations and coverage decision processes similar to
other molecules. AHTAPol’s reimbursement recommendations are based on evi-
dence of clinical benefit and efficacy/safety ratio, cost-effectiveness, costs and their
impact on the payer’s budget. METHODS: Among recommendations of AHTAPol
published until the end of May 2011, we identified all related to orphan oncology
drugs. Having categorized into types of recommendations then we analyzed ratio-
nal for granted decision. RESULTS: Among 420 AHTAPol decisions analyzed, 32
(21,7%) applied to non-drugs technologies, 91 (21,7%) to health care programs and
297 (70,7%) to drugs technologies. Among 297 drugs recommendations only 15 (5%)
was related to oncology orphan molecules. Granted were 10 (out of 15) positive
recommendations. For 3 out of 15 drugs AHTAPol issued conditional recommen-
dations (with restriction related to reducing the cost- effectiveness outcomes).
Only two orphan oncology drugs were assessed negatively. In both cases main
criteria on which recommendations were based refer to low clinical efficacy and
safety. CONCLUSIONS: Neither cost-effectiveness nor costs and budget impact
were significant arguments in negative recommendations of AHTAPol. As a matter
of fact, lack of clinical efficacy and insufficient safety profile were the key issues for
orphan oncology drugs negatively assessed by AHTAPol.
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OBJECTIVES: Methadone maintenance programs (MMP) offer the best treatment
for opioid dependence. In Spain, methadone hydrochloride is prepared as a magis-
tral formulation. Despite the organization and the management of the MMP is in
hands of the Delegación del Gobierno para el Plan Nacional sobre Drogas, each
autonomous region (AR) is responsible for its planning and financing. The aim of
this study was to identify planning MMP differences among AR in Spain.
METHODS: A structured literature review on the IME, SciELO, Doyma, Medline,
national and AR official bulletins and health web pages, and general and spe-
cialised press, up to July 1, 2010. RESULTS: Planning differences were found around
four areas. First, in 13 AR the regional health department establishes the health
care provision and legal framework for MMP, whereas in 4 AR this is a shared
responsibility between health and social security regional departments. Second,
three health care networks for the provision of MMP coexist in Spain. Andalusia
has drug care centers, 6 AR specialized or mental health centers and 10 AR combine
both structures. Third, in 11 AR methadone prescribing and dispensing is per-
formed in one center, in 6 AR in separate centers and in Cantabria coincide both
systems. Fourth, in the majority of AR a central laboratory or the hospitals elabo-
rate the greater part of the methadone; however, in 2 AR it is elaborated in phar-
macies and in 2 AR in the prescribing center. CONCLUSIONS: In Spain, patients are
not always normalized into the health care system. Methadone provided in the
MMP shows different elaboration, prescribing and dispensing processes across the
different AR. This may lead to heterogeneity in the magistral formulation of meth-
adone and patient access to it across the territory.
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OBJECTIVES: IEGM (General Directorate of Pharmaceuticals and Pharmacy) is re-
sponsible for setting all human medicinal products prices. Reference pricing sys-
tem is used for setting prices. Reference countries are reviewed annually and may
be subject to certain alterations. The aim of this study is to show the distribution of
reference countries which were used for reference pricing. METHODS: The price
list of pharmaceuticals which was published by IEGM on 15.04.2011 was used for
the analysis. Distribution of reference countries and prices were evaluated.
RESULTS: Prices of 6251 jeneric and 3703 original products were set. 5283 of jenerics
and 3306 of originals were in the positive list for reimbursement. Reference pricing
was used for 2352 jenerics and 2281 originals. Prices of the remaing were set outside
of reference pricing. 32 different countries were used for reference pricing. Italy
was the most popular country for reference pricing (24.47%). Italy was followed by
Spain (21.96%), Greece (19.69%), France (11.8%) and Portugal (8.7%). Even if Germany
was not a reference country, Germany was used in 3.71% of pharmaceuticals. Other
25 countries were used by 13,29%. However the ranking was changed only in phar-
maceuticals with prices above 200 Turkish Liras (TL) or original pharmaceuticals;
Greece was the most popular country in these rankings by 27.85% and 24.25%,
respectively. Italy was the most popular country for reference pricing in sub groups
like generics, prices ranging between 0 and 50 TL, 50 and 100 TL, and 100 and 200 TL.
CONCLUSIONS: It has been shown that Italy has the highest impact on the pricing
of all pharmaceuticals in Turkey. Greece has the highest impact on the pricing of
originals. Even if Germany was not a reference country, it has been seen that it
affects pharmaceuticals more than other countries which were also not used for
reference pricing.
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OBJECTIVES: The role that payers play in the pharmaceutical market has been
increasing in prominence. Much research has focused on public payers and how
drug reimbursement policies change in response to data from drug effectiveness
studies. However, the commercial payer perspective has not been well researched.
This study seeks to describe how U.S. commercial payers use different types of
comparative evidence to make reimbursement and formulary placement
decisions. METHODS: We recruited 20 US commercial payers who currently par-
ticipate in or lead pharmaceutical and therapeutics committees for their plans. Our
participants represent managed care organizations that cover a total of more than
95 million members. We conducted semi-structured qualitative interviews com-
prised of five representative scenarios and asked payers to rate how they value
different study designs for each scenario. The interviews were transcribed, the
responses were tabulated, and then analyzed for content. RESULTS: The reported
value of the study designs differed between national and regional payers as well as
between medical and pharmacy directors. National payers have more resources
and are more likely to value and conduct retrospective analyses and decision mod-
eling than regional payers. Pharmacy directors tend to favor retrospective analyses
and medical directors value RCTs, pragmatic trials, and prospective non-experi-
mental studies. Although RCTs were often the highest ranked study design, payers
still found prospective non-experimental studies and retrospective analyses valu-
able for certain uses. Payers are currently unable to manage most oncology prod-
ucts beyond labeled indications due to political pressure to cover all drugs regard-
less of price. CONCLUSIONS: Payers value and utilize data from a broad range of
study designs to inform formulary placement decisions. However, the disease
state, market condition, and type of payer will influence what sort of comparative
evidence is of the most value.
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OBJECTIVES: Emergency Department (ED) overcrowding (OC) is plaguing EDs
worldwide with grave implications on patient and caregiver comfort and quality of
care. Alleviating this problem tops agendas of governmental and professional
agencies. Many contributing factors have been cited and many approaches have
been tried, without widespread success. Focused Operations Management (FM)
integrates novel managerial theories and practical tools {such as the theory of
constraints (TOC) and the Pareto diagram} into a systematic approach, helping
managers to analyze complex operational systems, find bottlenecks and root
causes and finally, chart routes to improved throughput and quality. This approach
has proved effective in the industry and service sectors, radically improving per-
formance at little additional cost. The FM approach has never been implemented in
the ED and could considerably enhance the management of its operations. In this
first phase of the research, we use semi-structured interviews with experts, to
identify potential high-yield interventions. METHODS: A review of the ED opera-
tions literature was performed to identify major ED operational challenges, metrics
and alleviating measures. Semi-structured interviews with ED head nurses and
managers, hospital administrators and Health ministry administrators were con-
ducted. The interviews centered on validation of major challenges identified in the
literature search and assessing potential utility of FM tools. RESULTS: The major
challenges we identified included ED boarding, prolonged length of stay, unjusti-
fied ED utilization and slow access to specialist consults, lab tests and imaging
studies. Of the FM tools presented to specialists, those assessed to be most prom-
ising were ”the “complete kit” concept and TOC methods to identify and alleviate
bottle necks and to reduce “work in progress”. CONCLUSIONS: implementation of
the novel FM management strategies has enhanced operations and performance in
many industries and services. The ED is in dire need and a good candidate for the
use of these tools.
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OBJECTIVES: To describe the use of paediatric “observation status” in the accident
and emergency department (A&E). METHODS: A prospective survey was per-
formed in 12 Belgian hospitals during 2 weeks straddling October and November
2010. All patients (16 years) attending A&E were included. “Observation status”
was defined when after the first medical evaluation, instead of hospitalization or
home discharge, the situation required further observation of the patient. The
clinicians in charge were asked at the start of the “observation” period to prognos-
ticate whether the child would be discharged or admitted. RESULTS: Among 3220
children included in the study, the observation rate was 38.6%. The characteristics
of these children were as follows. Median age: 5.0 years old (IQR: 1.7-11.3), boys:
53.5%. The median length of stay in A&E was 110 minutes (IQR: 65-175) and 14.3%
were admitted as in-patient. The most common observations concerned orthopae-
dic, medical digestive and respiratory affections. The three main reasons for ob-
servation were additional procedures (69.0%), diagnostic determination (10.7%),
and treatment testing (8.3%). Most of the observations (86.9%) were performed in a
waiting room (not in a bed), 9.7% in an observation unit dedicated to children and
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